Novel insights for the treatment of Alzheimer's disease

Progress in Neuro-psychopharmacology & Biological Psychiatry
Alexander Kurz, Robert Perneczky

Abstract

The development of treatments for Alzheimer's disease (AD) is currently shifting away from the correction of neurotransmitter abnormalities and from attempts to remove the pathognomonic protein deposits. Drug discovery is heading towards novel types of pharmacological interventions which are aimed at more central and upstream pathophysiological events. The large number of upcoming treatment targets can be grouped into two major categories. The first category consists of antecedents of beta amyloid peptide (Aβ) and TAU deposition including Aβ production, degradation and clearance, TAU hyperphosphorylation and aggregation. The second consists of protectors against neuronal dysfunction and premature death such as mitochondrial functioning, nerve growth and regeneration, and neuronal membrane integrity. It is hoped that some of these strategies will not only have larger symptomatic effects than the currently available drugs but also an impact on the underlying neurodegeneration. Since the novel treatments will be typically administered over years they must meet high standards of safety, drug-drug compatibility, and tolerability. Probably the most important target groups for novel treatments are carriers of mutations causing AD, and...Continue Reading

References

Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·J T GreenamyreA B Young
Aug 1, 1988·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·C Waters
Jul 30, 1982·Science·R T BartusA S Lippa
Aug 14, 1998·Dementia and Geriatric Cognitive Disorders·M Eriksdotter JönhagenL O Wahlund
Sep 6, 2000·Dementia and Geriatric Cognitive Disorders·A Maelicke
Sep 6, 2002·Journal of Alzheimer's Disease : JAD·Xue-Qing ChenWilliam H. Frey II
Apr 12, 2003·Trends in Neurosciences·Ashley I Bush
Jul 11, 2003·Annals of the New York Academy of Sciences·Sergey O BachurinSergey O Sablin
Aug 5, 2003·The Journal of Clinical Investigation·Jason L EriksenTodd E Golde
May 11, 2004·Drugs & Aging·Josef Marksteiner, Reinhold Schmidt
Dec 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Bin ZhangJohn Q Trojanowski
Apr 27, 2005·Nature Medicine·Mark H TuszynskiJames Conner
Jun 25, 2005·Current Alzheimer Research·John M RingmanJeffrey L Cummings
Jul 12, 2005·Pharmacology & Therapeutics·Ellen S Mitchell, John F Neumaier
Jan 20, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·X A AlvarezH Moessler
Feb 1, 2006·The Pharmacogenomics Journal·M E RisnerUNKNOWN Rosiglitazone in Alzheimer's Disease Study Group
May 24, 2006·Acta Neuropathologica·Rudy J CastellaniMark A Smith
Jul 22, 2006·Biochemical Society Transactions·J Peleshok, H U Saragovi
Jul 22, 2006·Lancet Neurology·Deborah Gustafson
Sep 23, 2006·Science·Michael WillemChristian Haass
Oct 13, 2006·Journal of Neural Transmission·P EikelenboomJ J M Hoozemans
Oct 14, 2006·Journal of Neural Transmission·R Schliebs, T Arendt
Nov 2, 2006·Journal of Neurochemistry·Todd E Golde
Apr 4, 2007·Neurobiology of Aging·Fernanda G De FeliceWilliam L Klein
Apr 27, 2007·Neurology·UNKNOWN ADAPT Research GroupM Sabbagh
Jun 30, 2007·Pharmacology & Therapeutics·Raymond D PriceNobuya Matsuoka
Oct 3, 2007·Current Alzheimer Research·Paul S AisenDenis Garceau
Oct 17, 2007·Neurology·Jeffrey L CummingsChristopher Clark
Nov 30, 2007·Clinical Interventions in Aging·Carolyn W Zhu, Mary Sano
Dec 20, 2007·Journal of Neurochemistry·Claudie HooperSimon Lovestone
Jan 18, 2008·The Journal of Pharmacology and Experimental Therapeutics·Yasuji MatsuokaPaul S Aisen
Apr 9, 2008·Dementia and Geriatric Cognitive Disorders·Martin R FarlowVojislav Pejovic
May 3, 2008·Lancet Neurology·Gordon K WilcockUNKNOWN Tarenflurbil Phase II Study investigators
May 10, 2008·Expert Review of Proteomics·Nicolas SergeantLuc Buée

❮ Previous
Next ❯

Citations

Jun 29, 2013·International Psychogeriatrics·Alexander KurzNicola T Lautenschlager
Sep 6, 2012·International Journal of Molecular Sciences·Paweł SzymańskiElżbieta Mikiciuk-Olasik
Jun 27, 2015·Pharmaceutical Research·Xiaoyao ZhengXinguo Jiang
Aug 3, 2014·Expert Opinion on Pharmacotherapy·Alexander Kurz, Timo Grimmer
Aug 25, 2016·Bioscience, Biotechnology, and Biochemistry·Lushuang XieYan Fu
Mar 2, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Syed Haris Omar
Aug 3, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jong Kil Lee, Nam-Jung Kim
May 8, 2018·Nutrients·Yan Yan JinSeong-Tschool Hong
May 29, 2018·Reviews in the Neurosciences·Ghazaleh KheiriNima Rezaei
Apr 22, 2011·Neurochemical Research·M ObulesuR Somashekhar
Feb 26, 2015·Pharmacological Reports : PR·Anil Kumar Ekavali
Jan 1, 2020·Biomolecules·Gabriela Dumitrita StanciuDaniela Carmen Ababei
Jun 11, 2020·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Masoomeh KhalifehAmirhossein Sahebkar
Oct 25, 2016·Clinical Medicine Insights. Pathology·Apurva KulkarniLauren A O'Donnell
Jul 25, 2018·Journal of Alzheimer's Disease : JAD·Barry McDermottMarggie Jones
Nov 20, 2016·Journal of Molecular Neuroscience : MN·Niyaz Mohammadzadeh HonarvarGerald Muench
Jul 1, 2017·JAD Reports·Md Rashidur RahmanMostakim Sharif
Oct 18, 2019·Expert Opinion on Drug Discovery·Miroslava Cuperlovic-Culf, Amanpreet Badhwar
Jun 14, 2018·Frontiers in Pharmacology·Bushra ShalSalman Khan
Dec 4, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ching-Hsuan ChouChia-Ron Yang
Feb 25, 2021·Translational Neuroscience·Min LiXuezhen Wang
Nov 9, 2017·Molecular and Cellular Neurosciences·Roy LardenoijeBart P F Rutten
Jun 3, 2021·International Journal of Molecular Sciences·Ching-Hsuan Chou, Chia-Ron Yang
Aug 13, 2021·Mediators of Inflammation·Mashoque Ahmad RatherMuneeb U Rehman
Jul 11, 2019·Journal of Natural Products·Jou-Man HuangChia-Ron Yang
Aug 28, 2021·Life Sciences·Dapinder KaurSimona Bungau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Microglia

Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.